Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Effects of Morning Blue-Green 500 nm Light Therapy on Cognition and Biomarkers in Middle-Aged and Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment: Study Protocol for a Randomized Controlled Trial

This study aims to provide evidence of the impact of light therapy on subjective and objective cognitive performance in middle-aged and older adults with SCD or aMCI.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

This is a study protocol for a planned randomized controlled trial of morning 500 nm blue-green light therapy in adults aged 45 or older with subjective cognitive decline or amnestic mild cognitive impairment. The authors describe planned outcomes including cognition, sleep, mood and biomarkers, but no results are reported in the abstract.

Who or what was studied
Middle-aged and older adults aged 45 years or older with subjective cognitive decline or amnestic mild cognitive impairment, recruited from memory clinics, plus healthy controls; planned total of 150.
Wavelengths
500 nm
Limits stated in the abstract
This is a protocol only, so no efficacy findings are reported, and the abstract describes a single-center trial with a planned 4-week duration.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.

Record from PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
500 nm

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Mild cognitive impairment, Cognitive decline, Randomized controlled trial, Primary outcome. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Brain & Neurology

A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial

Cognitive, metabolic, and network-level findings are consistent with enhanced mitochondrial efficiency and anti-inflammatory effects. These results support larger, double-blind, multicenter trials to evaluate tPBM as a mitochondria-targeted therapy in early ADRD.

Trial · June 3, 2026 · Rashidi-Ranjbar N et al.